Jan 25, 2015 at 16:54 | Source: PTI
Drug major Sun Pharma's top executive Dilip S Shanghvi expects the USD 4-billion Ranbaxy deal to be concluded by middle of next month while stating that the key challenge before the combined entity would be to rebuild the confidence of health regulators.
Jan 23, 2015 at 10:38 | Source: Reuters
Ipca had voluntarily halted shipments to the United States from the plant in July last year after the FDA outlined half a dozen violations including data integrity issues.The FDA announced the ban, called import alert, in a notice on its website late on Thursday. It did not elaborate
Jan 07, 2015 at 15:54 | Source: Firstpost.com
Narendra Modi is taking a leaf out of Vajpayees book, only this time it is a whole branch, and not just a leaf. Rs 2,00,000-3,00,000 crore is one helluva public investment stimulus. It would range from 1.4-2.1 percent of potential GDP in 2015-16.
Jan 06, 2015 at 11:09 | Source: Moneycontrol.com
"Jubilant received abbreviated new drug application (ANDA) final approval from the US Food and Drug Administration (US FDA) for Mycophenolate Mofetil USP and Rizatriptan," said the pharmaceuticals and life sciences company in its filing to the exchange.
Jan 05, 2015 at 13:51 | Source: CNBC-TV18
Revenue growth for the global pharmaceutical company stands at 15 percent for FY15 and 25 percent for FY16. Going ahead, the company awaits FDA approval for their new plant, C Krishna Prasad adds.
Dec 19, 2014 at 15:58 | Source: PTI
The collaboration has been established for an oral controlled release product utilising Panacea's platform of oral drug delivery technology, Panacea Biotec Ltd said in a statement.
Dec 08, 2014 at 21:14 | Source: PTI
The nationwide recall has been initiated by the company on October 1 this year and has been initiated under Class-III which FDA defined as "a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences".
Dec 02, 2014 at 08:34 | Source: Moneycontrol.com
Sun Pharma Advanced Research Company announced that the US Food and Drug Administration (FDA) has issued a Complete Response letter to its New Drug Application (NDA) for Latanoprost BAK-free eyedrops.
Nov 26, 2014 at 14:34 | Source: PTI
Ranbaxy Laboratories had sued USFDA over revoking an approval to sell generic versions of Nexium and Valcyte in the US market.
Nov 21, 2014 at 11:33 | Source: Moneycontrol.com
The brokerage says Cipla aims to grow its sales from USD 1.6 billion to USD 5 billion by FY20 (21 percent compounded annual growth rate - CAGR).